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Glioma-initiating cells/glioma stem cells (GIC/GSCs) are grown in vitro using a cumbersome and inefficient
spheroid assay. In this issue of Cell Stem Cell, Pollard and coworkers present a protocol for the efficient
derivation of GIC/GSC lines that may greatly improve the isolation and the potential clinical application of
these cells.
The cancer stem cell hypothesis (CSCH)
posits that a subpopulation of cells within
a tumor has true clonogenic and tumori-
genic potential. Experimental data from
a number of tumor types, including glio-
mas, have demonstrated the existence
of a unique population of tumor/glioma-
initiating cells (GICs) consistent with the
CSCH. A more controversial correlate to
the CSCH is that these GICs have biologic
characteristicsofembryonicand/or tissue-
restricted stem cells, loosely defined as
self-renewal capacity, and the ability to
differentiate along tissue-specific lineage.
Indeed, glioma-derived GICs are isolated
from human gliomas using cell culture
techniques pioneered for the isolation of
normal neural stem cells (NSC) (Singh
et al., 2003; Galli et al., 2004). Specifically,
tumor cells are grown as nonadherent
spheroid-forming cells in the presence of
a limited repertoire of defined growth
factors and in the absence of serum. The
ability to grow as spheres, or ‘‘neuro-
spheres,’’ has come to be accepted as
a defining property of both NSC and
glioma-initiating cells/glioma stem cells
(GIC/GSC). Work presented in this issue
ofCell StemCell by Pollard and coworkers
calls into question the reliability and utility
of the spheroid-forming assay for isolating
glioma GIC/GSC and offers a potentially
much improved methodology for growing
such cells (Pollard et al., 2009).
The use of the spheroid assay for
isolating glioma GIC/GSC is associated
with at least three general problems. First,
the efficiency of successfully isolating
established GIC/GSC lines from any
given tumor is low (from 1%–30%) and
has been attributed to the tendency of
spheroid cells to spontaneously undergo
differentiation and/or apoptosis during
serial passage, as shown by Pollard and
others (Pollard et al., 2009; Beier et al.,
2008; Laks et al., 2009). The second
problem is that only a small percentage of
the cells within a spheroid are true GIC/
GSC, with the majority of cells being
partially or fully differentiated and/or dying
progeny (Bez et al., 2003). Finally, the
finicky and nonadherent growth character-
istics of the spheroid cells make molecular
analyses challenging and cross compari-
sons between labs difficult, even when
using the same cells. Furthermore, the
spheroid growth conditions greatly hinder
the potential use of GIC/GSCs in high-
throughput assays, such as genetic and
drug screens.
Applyingmethodologies previously em-
ployed to develop a more efficient system
for growing NSC in vitro (Sun et al., 2008),
this group demonstrates that, through
a simple manipulation of the standard
spheroid assay protocol, GIC/GSCs can
now be grown as an adherent monolayer.
Pollard et al. employed a simple mechan-
ical and enzymatic digestion of fresh
surgically removed human glioma tissue
and then plated the single-cell suspension
on laminin-coated cell culture plates along
with standard NSC culture media and
growth factors. The result was a mono-
morphic population of cells that had
many of the characteristics used to define
GIC/GSCs, such as expression of NSC
markers (e.g., Nestin, Sox-2, and Olig2),
the ability to differentiate along both
neuronal (e.g., Tuj1 expression) and glial
lineages (e.g., expression of GFAP, O4),
a genomeharboringgenetic abnormalities
consistent with the parental tumor, and
the ability to form highly infiltrative tumors
when transferred to the brains of immuno-
deficient mice. Most importantly, these
adherent cultures appear to be capable
of long-term serial passage, to consist of
a high percentage of true GIC/GSCs with
significantly fewer spontaneously differ-
entiating or apoptotic cells, and can be
derived from nearly 100% of primary
malignant gliomas, in contrast to the very
low efficiency of deriving such cell lines
from primary tumors using the spheroid
assay.
One possibility for the improvement in
the new methodology compared with the
spheroid protocol is that the physical
and geometric constraints of a growing
spheroid limit the diffusion of culture
media and its constitutes to internal cells,
thereby setting up gradients of nutrient,
oxygen, and growth factors within the
spheroid, all important determinants
for stem cell proliferation, differentiation,
anddeath (Figure1).Bycontrast, adherent
cellswithin amonolayer have amuchmore
homogeneous exposure to such factors.
This still, however, does not explain why
GIC/GSCs adhere to and grow so effi-
ciently on laminin-coated dishes when
they spontaneously form spheroids and
undergo spontaneous differentiation on
other substrates such as gelatin or polyor-
nithine. This might suggest that interac-
tions of laminin with GIC/GSC integrins or
other extracellular matrix components
result in signals that inhibit stem cell differ-
entiation. Notably, laminin-1 is not found in
the central nervous system, so perhaps
laminin is conducive to the GIC/GSCs
producing their own extracellular matrix
that maintains them in an undifferentiated
state, as might be occurring in vivo in the
stem cell niche (Ekblom et al., 2003).
The potential practical implications of
this technological advancement are
clear. First, the simple ability to expand
a homogeneous population of GIC/GSC
will significantly facilitate studying their
molecular and cellular biology with less
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concern for the nonclonogenic contami-
nating cells (i.e., the ability to obtain more
accurate global gene expression profiles).
Furthermore, it should make it easier to
define GIC/GSC-specific markers of pure
GIC/GSC populations for developing clin-
ical diagnostic tools and/or immunothera-
peutic strategies directed against these
specific epitopes, as has been done in
hematological cancers (Nasr et al., 2008).
Another significant advantage for this
stemcell culture technique is that adherent
cells lend themselves to the development
of high-throughput assays and screens
to a much greater extend than do floating
spheroids. Such adherent cells would
work well for high-throughput siRNA
screens for probing genetic determinants
of ‘‘stemness’’ and tumorigenecity. Like-
wise, such cells will lend themselves
to high-throughput screens of chemical
libraries in attempts to define novel cyto-
toxic, cytostatic, and differentiating mole-
cules that might ultimately form the basis
for novel therapeutic drug development.
Pollard and coworkers provide proof of
principle for how these cells might be
used for chemical assays by screening
in vitro 450 FDA-approved drugs for
potential antiglioma activity and identifying
23 compounds with cytotoxic activity on
all tested GIC/GSC lines and another
15 compounds that had line-specific cyto-
toxic effects.
Finally, andpossiblymost exciting, is the
potential of being able to establish a GIC/
GSC line for every patient undergoing
surgery for a malignant glioma, given the
significantly improvedefficiencyofderiving
such lines from tumor tissue using the
methodology by Pollard and coworkers.
In vitro drug screening of patient-specific
tumor cells, for the purpose of predicting
clinically active agents, has been unsuc-
cessful, most likely because the standard
tumor cell lines that have been historically
grown from fresh tumor tissue bear little
resemblance to the in situ tumor. With
the growing data that glioma GIC/GSC
show significantly greater similarity to their
parental tumors at the genetic, molecular,
and cellular levels comes the possibility
that drug sensitivity screening of GIC/
GSC may be much more successful at
identifying clinically useful therapeutic
agents for each individual tumor (Lee
et al., 2006; Pollard et al., 2009). Thus, in
addition to changing the paradigm of how
we think about tumor growth and its under-
lyingbiology, tumor stemcellsmayhold the
key to improved therapy and to an entirely
neweraof ‘‘personalizedoncologicalmedi-
cine.’’ The work by Pollack and coworkers
moves us one step closer to that Promised
Land.
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Figure 1. Glioma Tumor Stem Cells Cultured as Spheroids, in Contrast to Adherent Cells,
Promote Differentiation and Apoptosis
(A) In small spheroids, GSC/GICs are equally exposed to stem cell self-renewal growth factors and
hypoxia, conditions that maintain a majority of cells in a stem-like state (represented in blue).
(B) When tumor spheroids coalesce or grow larger, the percentage of stem-like cells dramatically
decreases due to poor diffusion of growth factors and an increase in central hypoxia or prodifferentiation
signals produced from lineage-committed offspring (represented in green).
(C) Culture on an adherent laminin surface allows for a more uniform exposure to growth factors and
oxygen. Decreased cell-cell contact and integrin/laminin signaling may also maintain the stem-cell like
state by limiting prodifferentiation signaling.
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